Co-Diagnostics

Co-Diagnostics Financing Cash Flow

The Net Financing Cash Flow of Co-Diagnostics (CODX) as of Nov 20, 2026 is 11.81 M USD. In the previous year, Net Financing Cash Flow was 103,914.00 USD — a change of 11,266.69% (higher).

Financing Cash Flow

11.81 MUSD

YoY

11,266.69%

Last updated:

Net Financing Cash Flow of Co-Diagnostics is 2025 11.81 M USD. Net Financing Cash Flow of Co-Diagnostics was 2024 103,914.00 USD. It decreases by 11,266.69% higher compared to the previous year.

The Co-Diagnostics Financing Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financing Cash Flow
Date
Financing Cash Flow
Jan 1, 2018
1.88 M USD
Jan 1, 2019
5.90 M USD
Jan 1, 2020
19.74 M USD
Jan 1, 2021
450,398.00 USD
Jan 1, 2022
-14.03 M USD
Jan 1, 2023
-1.36 M USD
Jan 1, 2024
103,914.00 USD
Jan 1, 2025
11.81 M USD
The Co-Diagnostics Financing Cash Flow history
YEARFinancing Cash FlowYoY
11.81 MUSD+11,266.69%
103,914.00USD-107.62%
-1.36 MUSD-90.28%
-14.03 MUSD-3,215.91%
450,398.00USD-97.72%
19.74 MUSD+234.44%
5.90 MUSD+214.65%
1.88 MUSD-68.40%
5.94 MUSD+159.30%
2.29 MUSD+56.81%
1.46 MUSD+26.41%
1.15 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Co-Diagnostics Stock analysis

What does Co-Diagnostics do? Co-Diagnostics, Inc. develops and sells diagnostic tests using proprietary reagents and a test design system for diseases and pathogens including tuberculosis, drug-resistant tuberculosis, hepatitis B and C, malaria, dengue, HIV, and Zika virus. The company also markets self-contained lab systems (MDx devices) from other manufacturers. Its products are sold to laboratories and healthcare providers for molecular testing of organisms and genetic diseases, automating complex procedures in test development and administration. The firm generates revenue through the sale of diagnostic reagents, validated tests, and MDx devices. The company's diagnostic technology focuses on nucleic acid detection and analysis, enabling molecular testing for various pathogens and genetic conditions. Its proprietary system allows for the design and validation of tests in-house, which are then marketed to healthcare institutions. Revenue streams include reagent sales, test kits, and equipment from partner manufacturers. Co-Diagnostics, Inc. targets laboratories and healthcare providers as key customers for its diagnostic solutions. The firm's products are designed to streamline molecular testing processes, reducing the complexity of traditional methods. This approach supports the company's revenue model based on direct sales of its proprietary tests and complementary equipment. Co-Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Co-Diagnostics stock

Net Financing Cash Flow of Co-Diagnostics is 11.81 M USD in 2025.

Net Financing Cash Flow of Co-Diagnostics changed from 103,914.00 USD to 11.81 M USD, representing a 11,266.69% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Financing Cash Flow Co-Diagnostics since 2006 – with annual values, charts, and detailed analysis.

Financing cash flow measures cash flows from debt issuance/repayment, equity transactions, and dividend payments.

Net Financing Cash Flow's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Financing Cash Flow's Co-Diagnostics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Co-Diagnostics

All Key Metrics — Co-Diagnostics